Enabling children and young people with epilepsy and related conditions to thrive and reach their ambitions
A- A A+
Donate Shop Main Number: 01342 832243 (Mon-Fri, 8:30am-5pm)
Helpline: 01342 831342 (Mon-Fri, 9am-3pm)

Pharmacokinetics, efficacy and safety of brivaracetam

The pharmacokinetics, efficacy and safety of brivaracetam in children with repeated electrographic seizures (PETITE)

Project aim

An international project to provide data on the long-term safety and efficacy of brivaracetam (BRV) in paediatric patients with epilepsy.

What this means

We want to understand the best way to use brivaracetam in children with epilepsy.


Ronit Pressler, Marios Kaliakatsos


We plan to recruit 600 participants across Europe, Mexico and the US with the possibility of adding more countries/regions as required. Participants will be aged between one month to <17 years whom have completed core studies, with at least another 100 participants between the ages of four years and <17 years of age who have been diagnosed with partial-onset seizures being directly enrolled into the study.

Participants will receive BRV for at least three years based on the development of approval for BRV, the establishment of a BRV access programme, or if the investigational product is stopped by the sponsor in the specific age group for the participant.

Several assessments will be carried out during the period of participation in the study which has been open since late 2017.

Read more about other research projects

Cyber EssentialsFundraising RegulatorYoung Epilepsy is the operating name of The National Centre for Young People with Epilepsy (NCYPE).
Registered Charity number 311877 (England and Wales)

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site
EU Cookie Directive plugin by www.channeldigital.co.uk